September 26, 2024 09:00 PM EDT
Startups
Special

End­points 11 win­ner Car­du­ri­on Phar­ma­ceu­ti­cals: A shot at one of heart dis­ease’s 'un­drug­gable' tar­gets

Lei Lei Wu

News Reporter

↑
  • CEO Pe­ter Lawrence
  • To­tal raised More than $500 mil­lion
  • Head­quar­ters Burling­ton, MA

‘Un­drug­gable’ tar­gets aren’t just in on­col­o­gy. Car­du­ri­on Phar­ma­ceu­ti­cals …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times